Etelcalcetide

The calcium-sensing receptor on parathyroid chief cells sets the threshold at which PTH is released. Etelcalcetide forms a reversible disulfide bond with cysteine 482 on the receptor's extracellular domain, a genuinely unusual mechanism that locks the receptor into a more active conformation and amplifies signalling from ambient calcium. The result is a sharp fall in PTH secretion, followed over time by reduced parathyroid cell proliferation. Being built almost entirely from D-amino acids makes it resistant to proteolysis, and it is cleared largely by dialysis and by reversible binding to plasma albumin, which is why it can be given three times weekly at the end of each session. In head-to-head trial against cinacalcet it reduced PTH more effectively, at the price of more hypocalcaemia.

Targets: Calcium-sensing receptor, Parathyroid hormone secretion, Parathyroid gland hyperplasia

• · Start 5 mg three times weekly. Titrate in 2.5 or 5 mg steps no more often than every 4 weeks, to a maximum of 15 mg three times weekly.

Work out your exact syringe units →

• very commonHypocalcaemia, often asymptomatic— The dominant effect. Roughly two thirds of patients drop below 8.3 mg/dL at some point.
• very commonNausea and vomiting— Less than oral cinacalcet but still frequent.
• commonSymptomatic hypocalcaemia: paraesthesia, muscle spasms, tetany— Requires dose interruption and calcium replacement.
• commonDiarrhoea
• uncommonQT prolongation from hypocalcaemia— Ventricular arrhythmia and seizures have been reported when calcium falls sharply.
• rareWorsening heart failure— Attributed to reduced myocardial contractility with hypocalcaemia.

• Corrected serum calcium below the lower limit of normal at initiation
• Known hypersensitivity to etelcalcetide
• Switching directly from cinacalcet without a 7-day washout

• cautioncalcitonin-salmon — Both lower serum calcium; combined use risks symptomatic hypocalcaemia.
• conflictpth-1-84 — Directly opposing intentions on the PTH axis.

• · Corrected serum calcium before starting, within 1 week of any dose change, then monthly
• · Intact PTH every 4 weeks during titration
• · Serum phosphate
• · ECG in patients with QT risk factors

Prescription drug in the US and EU, administered in dialysis units.

• Parsabiv FDA prescribing information (label)
• Block et al. 2017 JAMA, etelcalcetide versus cinacalcet in haemodialysis patients with secondary hyperparathyroidism (trial)
• KDIGO clinical practice guideline for chronic kidney disease mineral and bone disorder (guideline)

This is one of the genuinely unusual mechanisms in peptide pharmacology and it is worth understanding precisely. The calcium-sensing receptor is a class C GPCR on parathyroid chief cells that sets the calcium threshold at which PTH is released. Conventional calcimimetics such as cinacalcet bind in the transmembrane domain as allosteric modulators. Etelcalcetide does something different: it forms a reversible disulfide bond with cysteine 482 in the receptor's extracellular domain. That is a covalent tether, not a conventional binding event, and it locks the receptor into a conformation that behaves as though ambient calcium were higher than it is. Downstream, Gq-phospholipase C signalling and increased intracellular calcium in the chief cell suppress PTH exocytosis within minutes, and over weeks reduce PTH gene transcription and parathyroid cell proliferation. The covalent mechanism explains the pharmacokinetics too: the same disulfide chemistry that tethers the drug to the receptor also tethers it to albumin, creating a large, slowly equilibrating reservoir that gives a 3 to 4 day effective half-life and a 3 to 4-fold accumulation over the 7 to 8 weeks it takes to reach steady state. Being built entirely from D-amino acids removes proteolysis as a clearance route. The clinical consequence is a drug that is more potent than cinacalcet at lowering PTH and correspondingly more likely to produce hypocalcaemia, which is not a side effect so much as the same pharmacology carried one step too far.

Hypocalcaemia is the whole story, and it is often asymptomatic until it is not. Two thirds of patients drop below 8.3 mg/dL at some point, and the dangerous presentations, QT prolongation, ventricular arrhythmia, seizures and worsening heart failure, tend to follow a sharp fall rather than a chronic low level, which is why the calcium check within a week of every dose increase matters more than the monthly one. The second failure is titrating on PTH too fast: the drug takes 7 to 8 weeks to reach steady state and accumulates 3 to 4-fold, so escalating at 2 weeks means you are stacking doses on a rising baseline. The third is switching from cinacalcet without the 7-day washout. The fourth is starting in a patient whose corrected calcium is already at or below the lower limit of normal, which the label prohibits. The fifth is over-suppression: driving PTH below about 100 pg/mL in a dialysis patient risks adynamic bone disease, which is arguably worse than the hyperparathyroidism you were treating. And the honest framing: no trial has shown this drug reduces mortality, fractures or cardiovascular events, only PTH.

1. 5 mgWeeks 1-4 — 5 mg three times weekly at the end of dialysis, bolused into the venous line after rinse-back. Corrected calcium must be at or above the lower limit of normal before the first dose. If switching from cinacalcet, allow a 7-day washout.
2. 7.5 mgWeek 5 onward — Step up by 2.5 or 5 mg no more often than every 4 weeks, guided by PTH measured no earlier than 4 weeks after the last change, with corrected calcium checked within 1 week of the increase.
3. 10 mgContinuing titration — 10 mg three times weekly. Most responders settle somewhere between 5 and 12.5 mg.
4. 15 mgMaximum — 15 mg three times weekly is the ceiling. Doses can also be stepped down to a minimum of 2.5 mg three times weekly for hypocalcaemia or over-suppressed PTH.

• Calcium-sensing receptor, cysteine 482 in the extracellular domain — Binds by reversible disulfide exchange rather than conventional non-covalent binding; no Ki applies in the usual sense.

  Locks the receptor into an activated conformation, amplifying the signal from ambient calcium. PTH secretion falls within 30 minutes and parathyroid cell proliferation falls over weeks.

• Serum albumin — Reversible covalent disulfide conjugate; fraction-unbound ratio 0.53

  Not a target but a depot. The albumin conjugate is the reason for the 3 to 4 day effective half-life, the 3 to 4-fold accumulation and the 7 to 8 week time to steady state.

• Bone turnover markers

  Falling PTH reduces bone alkaline phosphatase and CTX over weeks, and over-suppression risks adynamic bone disease.

• Block 2017 etelcalcetide versus placebo Phase 3, randomised, double-blind, placebo-controlled (two parallel trials) · 2017

  Proportion of patients achieving a greater than 30 percent reduction in mean predialysis intact PTH during the efficacy assessment phase. Etelcalcetide was markedly superior to placebo in haemodialysis patients with secondary hyperparathyroidism.

• Head-to-head etelcalcetide versus cinacalcet Phase 3, randomised, double-blind, double-dummy active comparator · 2017

  Non-inferiority, then superiority, for the proportion of patients achieving a greater than 30 percent PTH reduction. Etelcalcetide reduced PTH more effectively than cinacalcet, at the cost of more hypocalcaemia. No trial in this programme has shown a mortality or fracture benefit.

PTH begins falling within 30 minutes of the first dose, which is dramatic but misleading, because the full effect on PTH and bone markers builds over weeks. Steady state takes 7 to 8 weeks with a 3 to 4-fold accumulation. Hypocalcaemia typically develops over the first few weeks and after each dose increase. Parathyroid gland size reduction, where it occurs, takes months. Any judgement of efficacy before 4 weeks at a given dose is premature.

Etelcalcetide is one lever of three in chronic kidney disease mineral and bone disorder, and it does not work alone. Phosphate binders control phosphate, active vitamin D analogues such as calcitriol or paricalcitol raise calcium and suppress PTH by a different mechanism, and the calcimimetic suppresses PTH without raising calcium or phosphate. The standard practice is to manage etelcalcetide-induced hypocalcaemia by adding calcium-based binders or increasing the vitamin D analogue rather than cutting the etelcalcetide dose, and the dialysate calcium concentration is a further lever that is easy to forget. Do not run etelcalcetide and cinacalcet together, and allow a 7-day washout when switching from cinacalcet, because the combination stacks hypocalcaemia. Combining with calcitonin or any other calcium-lowering agent risks the same. It is pharmacologically opposed to PTH replacement therapies.

Against cinacalcet: etelcalcetide reduced PTH more effectively in a head-to-head trial, and its decisive practical advantage is that it is given by the dialysis nurse into the circuit, which removes the adherence problem entirely. Cinacalcet is an oral daily tablet with prominent nausea and vomiting, and adherence in dialysis patients already taking a dozen medications is poor. The trade-off is more hypocalcaemia with etelcalcetide. Against vitamin D analogues: those suppress PTH but raise calcium and phosphate, which is exactly what you are trying to avoid, so calcimimetics and vitamin D analogues are complementary rather than competing. Against parathyroidectomy: surgery remains the definitive answer for severe refractory disease and is arguably underused, particularly given that no calcimimetic has demonstrated a hard outcome benefit. The EVOLVE trial of cinacalcet famously missed its primary composite endpoint, and that result colours how the whole class should be read.

$800–$2500/month. Unverified estimate for thrice-weekly dosing in the US. In practice this is usually bundled into dialysis facility reimbursement rather than billed to the patient, which changes the economics substantially compared with oral cinacalcet. Not sourced in this session.

• ?The protein binding figure of 47 percent is derived from the label's fraction-unbound ratio of 0.53 rather than being quoted directly as a percentage bound, and the binding is covalent and reversible rather than conventional, so the number does not mean quite what it usually means.
• ?The 52-day time to steady state is the midpoint of the label's 7 to 8 week range.
• ?Neither Block trial's enrolment nor duration was confirmed against the paper, so both are null.
• ?The head-to-head cinacalcet comparison is described from the same JAMA publication set; I confirmed the placebo-controlled paper but not a separate active-comparator publication, so its details are thinner.
• ?Cost figures are unverified estimates.

• Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials Block GA, et al., JAMA, 2017 · PMID 28097355

  The registration data. Note what the endpoint is: a biochemical PTH reduction, not a clinical outcome.

• PARSABIV (etelcalcetide) injection - FDA prescribing information Amgen, DailyMed

  Source of the 796 L volume of distribution, 7.66 L/h clearance, 3 to 4 day effective half-life, 7 to 8 week time to steady state with 3 to 4-fold accumulation, the reversible disulfide exchange biotransformation, the 60 percent recovery in dialysate and the full chemical name.